Helsana HealthInvest

Yazen is a digital healthcare platform specializing in personalized weight loss programs. It connects users with medical professionals, including doctors, dietitians, and personal trainers, to create tailored weight management plans combining lifestyle coaching and medical treatments.

Hedera Dx develops and commercializes liquid biopsy technology for hospital laboratories, enabling in-house clinically useful liquid biopsies that support tumor profiling and access to advanced diagnostic tools. The platform addresses regulatory compliance, privacy, and validation challenges and aims to simplify workflows that are currently inefficient. It offers early detection, therapy selection, and recurrence monitoring capabilities alongside aggregated clinical insights to help clinicians and researchers reduce cancer-related mortality and improve patient outcomes, while supporting drug development. Hedera Dx was founded on July 1, 2021 in Epalinges, Vaud.

Kenbi is a nurse-centric outpatient care company focused on enhancing the delivery of healthcare services. It provides outpatient care management aimed at supporting nurses and addressing gaps in the healthcare system. By leveraging technology, collegial organizational structures, and human-centric design, Kenbi organizes local care teams to deliver a range of outpatient and at-home services. These services include medical care covered by insurance, as well as household assistance, guidance, and companionship for patients. The company's approach is designed to reduce the time healthcare practitioners spend on bureaucratic tasks, allowing them to focus more on patient care and improving the overall experience for patients and their families.

Entyre is a healthcare technology company that operates an online platform to guide patients and caregivers through bureaucratic processes in the German healthcare system. Founded in 2017 and based in Hamburg, it leverages proprietary data and algorithms to collect outpatient data and support patients, physicians, and insurers in making better, more informed decisions. The platform is designed to identify and correct mismanagement in care, reduce unnecessary hospital stays, lower costs, and address opacity and complexity in the sector, with the aim of improving outcomes for individuals and the health system.

Humanoo is a digital health platform aimed at enhancing the physical and mental well-being of employees and insurance clients. The platform offers customized programs and innovative eHealth solutions in areas such as fitness, physiotherapy, yoga, mindfulness, and nutrition, helping users achieve their health goals. By providing comprehensive decentralized analysis, Humanoo enables companies and insurers to gain insights into the health of their employees or clients, facilitating measurable improvements. The team, comprised of 65 professionals from 15 countries, includes software developers, designers, marketing and sales specialists, as well as health and wellness experts such as sports scientists, nutritionists, yoga instructors, and physiotherapists. Humanoo's mission is to motivate individuals to maintain a healthy lifestyle and improve their overall productivity.

EPha.ch is a startup emerging from the University Hospital Zurich and the University of Zurich, focused on clinical pharmacology. The company comprises an interdisciplinary team of specialists, including pharmacists and computer scientists, who possess extensive expertise in drug therapy. EPha.ch has developed a digital AI-powered assistant that aims to prevent medication errors and enhance patient safety. By utilizing artificial intelligence and advanced algorithms, the platform evaluates the safety of polypharmacy and provides personalized medication alternatives and guidance. This enables healthcare providers to analyze and optimize medication plans for patients, ensuring timely and informed decision-making based on comprehensive drug information.

Hedera Dx develops and commercializes liquid biopsy technology for hospital laboratories, enabling in-house clinically useful liquid biopsies that support tumor profiling and access to advanced diagnostic tools. The platform addresses regulatory compliance, privacy, and validation challenges and aims to simplify workflows that are currently inefficient. It offers early detection, therapy selection, and recurrence monitoring capabilities alongside aggregated clinical insights to help clinicians and researchers reduce cancer-related mortality and improve patient outcomes, while supporting drug development. Hedera Dx was founded on July 1, 2021 in Epalinges, Vaud.